COVALENT-111 Phase 2b on track for Q4 2024 readout COVALENT-112 Phase 2a on track for Q4 2024 readout Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported se ...

COVALENT-111 Phase 2b on track for Q4 2024 readout COVALENT-112 Phase 2a on track for Q4 2024 readout Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported se ...

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. WHAT IS THIS ABOUT: On June 6, 2024, after the market closed, Biomea Fusion issued a press release entitled "Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold." It stated that the company had ...

NEW YORK, June 24, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. What is this about: On June 6, 2024, after the market closed, Biomea Fusion issued a press release entitled "Biomea Fusion Announces BMF-219 in Diabetes Placed ...

So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

The investigation concerns whether Biomea and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On June 6, 2024, Biomea issued a press release "announc[ing] that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVA ...

[Click here for information about joining the class action] CONTACT: Danielle Peyton Pomerantz LLP [email protected] 646-581-9980 ext. 7980 On this news, Biomea's stock price fell $7.13 per share, or 63.27%, to close at $4.14 per share on June 7, 2024. NEW YORK, June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biomea Fusion, Inc. ("Biomea" or the "Company") (NASDAQ: BMEA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ...

This clinical hold comes from the Food and Drug Administration (FDA) and has to do with safety concerns. The regulator is worried about possible drug-induced hepatotoxicity. This comes after the trials may have led to liver enzyme elevations. Biomea Fusion chairman and CEO Thomas Butler said the following about this clinical hold news. How This Affects BMEA Stock Today Investors will want to stick around for even more of the most recent stock market stories on Friday! On the date of publication, William Whi ...

So, how does a shorted stock become a short squeeze stock? It all depends on an unexpected event causing the stock's value to increase, which forces the investors who shorted the stock to buy themselves out of their short positions to mitigate losses. Because these investors exit the position through a buy signal, it causes even more value creation for the stock, creating a short squeeze and spiking the stock. This sharp spike resembles the wavelength of a gamma ray, hence why it is often referred to as a g ...